1. Home
  2. MEIP vs BHR Comparison

MEIP vs BHR Comparison

Compare MEIP & BHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • BHR
  • Stock Information
  • Founded
  • MEIP 2000
  • BHR 2013
  • Country
  • MEIP United States
  • BHR United States
  • Employees
  • MEIP N/A
  • BHR N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • BHR Real Estate Investment Trusts
  • Sector
  • MEIP Health Care
  • BHR Real Estate
  • Exchange
  • MEIP Nasdaq
  • BHR Nasdaq
  • Market Cap
  • MEIP 153.9M
  • BHR 171.6M
  • IPO Year
  • MEIP 2003
  • BHR N/A
  • Fundamental
  • Price
  • MEIP $4.91
  • BHR $2.12
  • Analyst Decision
  • MEIP
  • BHR
  • Analyst Count
  • MEIP 0
  • BHR 0
  • Target Price
  • MEIP N/A
  • BHR N/A
  • AVG Volume (30 Days)
  • MEIP 3.2M
  • BHR 171.7K
  • Earning Date
  • MEIP 09-18-2025
  • BHR 07-31-2025
  • Dividend Yield
  • MEIP N/A
  • BHR 9.48%
  • EPS Growth
  • MEIP N/A
  • BHR N/A
  • EPS
  • MEIP N/A
  • BHR N/A
  • Revenue
  • MEIP N/A
  • BHR $715,161,000.00
  • Revenue This Year
  • MEIP N/A
  • BHR N/A
  • Revenue Next Year
  • MEIP N/A
  • BHR $2.32
  • P/E Ratio
  • MEIP N/A
  • BHR N/A
  • Revenue Growth
  • MEIP 33.76
  • BHR N/A
  • 52 Week Low
  • MEIP $1.46
  • BHR $1.80
  • 52 Week High
  • MEIP $9.00
  • BHR $3.82
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 53.94
  • BHR 44.70
  • Support Level
  • MEIP $4.62
  • BHR $2.07
  • Resistance Level
  • MEIP $5.19
  • BHR $2.20
  • Average True Range (ATR)
  • MEIP 0.46
  • BHR 0.09
  • MACD
  • MEIP -0.16
  • BHR -0.00
  • Stochastic Oscillator
  • MEIP 15.93
  • BHR 35.14

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About BHR Braemar Hotels & Resorts Inc.

Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.

Share on Social Networks: